A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of
 ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with
 genotype 1 chronic hepatitis C virus infection.
Inclusion Criteria:

 -  US military veteran currently receiving healthcare through the Veterans Health
 Administration

 -  Screening laboratory result indicating hepatitis C virus (HCV), genotype 1-infection

 -  Positive for hepatitis C antibodies or HCV RNA at least 6 months before Screening, and
 HCV RNA > 1,000 IU/mL at the time of Screening or HCV RNA > 1,000 IU/mL at the time of
 Screening with a liver biopsy consistent with chronic HCV-infection (or a liver biopsy
 performed prior to enrollment with evidence of chronic hepatitis C disease)

 Exclusion Criteria:

 -  Women who are pregnant or breastfeeding

 -  Positive test result for hepatitis B surface antigen (HbsAg) or anti-HIV antibodies
 (HIV Ab)

 -  Prior or current use of any investigational or commercially available anti-HCV agents
 other than IFN, pegIFN, RBV or sofosbuvir

 -  Any current or past clinical evidence of Child-Pugh B or C classification

 -  Confirmed presence of hepatocellular carcinoma indicated on imaging techniques within
 3 months prior to Screening or on an ultrasound performed at Screening for
 participants with cirrhosis